BioSpace News Archive

CymaBay Therapeutics, Inc. announced positive topline results from ENHANCE, a placebo-controlled, randomized, Phase 3 study evaluating the safety and efficacy of seladelpar for the treatment of primary biliary cholangitis.

via NEWMEDIAWIRE – Brain Scientific Inc., a neurology-focused medical device and software company, announced that its common stock commenced trading as of July 29, 2020 on the OTCQB® Venture Market.

RedHill acquired Movantik® for opioid induced constipation from AstraZeneca in April 2020; Movantik® generated $96 million in 2019

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers, announced that both the United States Patent and Trademark Office and the European Patent Office have issued patents covering HOOKIPA’s proprietary replicating arenavirus technology.

PolyPid Ltd., a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, announced that D-PLEX100 has received Fast Track Designation from the U.S. Food and Drug Administration for the prevention of post abdominal surgery incisional infections.

Simcere to lead clinical development, regulatory submissions and commercialization of trilaciclib across all indications in Greater China

BD, a leading global medical technology company, issued its 2019 Sustainability Report, focusing on performance of the environmental, social and governance factors that support the company’s 2020 Sustainability Goals from October 1, 2018 to September 30, 2019.

Bio-Techne Corporation announced the appointment of Julie L. Bushman to serve as an independent director on the company’s board of directors, effective as of July 31, 2020.

ArcherDX, Inc., UCL and the Francis Crick Institute announced an extension to utilize personalized, liquid biopsy-based research assays for the duration of the TRACERx program, a major lung cancer research initiative funded by Cancer Research UK.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that members of its management team will participate virtually in the BTIG Biotechnology Conference on Monday, August 10, 2020 at 12:00 p.m. ET.